Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-8491
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia ; volume:272 ; number:1 ; day:17 ; month:1 ; year:2022 ; pages:1-3 ; date:2.2022
European archives of psychiatry and clinical neuroscience ; 272, Heft 1 (17.1.2022), 1-3, 2.2022
- Urheber
-
Leucht, Stefan
Davis, John M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00406-021-01378-1
- URN
-
urn:nbn:de:101:1-2022050821160362831370
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Leucht, Stefan
- Davis, John M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?
Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Stroke Risk Among Non-Elderly Users of Haloperidol or First-Generation Antipsychotics vs Second-Generation Antipsychotics: A Cohort Study from a US Health Insurance Claims Database
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
Current antipsychotics
Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?
Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Stroke Risk Among Non-Elderly Users of Haloperidol or First-Generation Antipsychotics vs Second-Generation Antipsychotics: A Cohort Study from a US Health Insurance Claims Database
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
Current antipsychotics
Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?
Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Stroke Risk Among Non-Elderly Users of Haloperidol or First-Generation Antipsychotics vs Second-Generation Antipsychotics: A Cohort Study from a US Health Insurance Claims Database
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics